Company intelligence / Profile preview

Curocell Inc.

Daejeon, Daejeon, South Koreacareofsweden.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 1

Overview

Curocell Inc. develops innovative CAR-T cell therapies using its proprietary OVIS™ technology to overcome limitations of existing treatments. Its lead asset, anbal-cel, targets multiple myeloma and T-cell lymphoma and may be the first homegrown Korean CAR-T therapy. The company has raised over $82 million in funding through Series D and continues to expand its pipeline targeting both blood cancers and solid tumors. It focuses on novel antigen discovery, improved efficacy/safety of cell therapies, and automation of quality analysis.

Therapeutic areas: HematologyOncology
Modalities: CAR-T cell therapies (chimeric antigen receptor T-cell therapies)
Industry: Biotech

Drug pipeline

1 asset

anbalcabtagene autoleucel

Beyond the preview

Go deeper on Curocell Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curocell Inc..

Explore the full profile